JP: not just MANF and Phenoguard. They would also

JP: not just MANF and Phenoguard. They would also have Eltoprazine and ESS. My gut tells me they are not going to sell the diagnostics division. They buy assets and build their value for future monetization. Most of them are still early and could be developed for more value. I could see a sale of Lympro, but why. The actions of AMBS building out their Alzheimers Biomarkers via Georgetown and 'cornering' the Alzheimers Diagnostics market is an awesome long term strategy that suggests just that, long term. I could see a Lympro sale but I could see a large equity diagnostics partner or Lympro partner coming on board that would light the fire for an uplist. That would both get a large sum of money up front with the promise of continued revenue.